[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100526159":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":31,"centralContacts":35,"locations":44,"responsibleParty":60,"collaborators":10,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":10,"enrollmentInfo":73,"targetDuration":10,"studyType":76,"phases":10,"briefSummary":77,"conditions":78,"keywords":10,"overallStatus":47,"whyStopped":10,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Rigshospitalet, Denmark","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A",null,"22 patients with clinically suspected cardiac sarcoidosis",[13],"Diagnostic Test: 64Cu-DOTATATE PET\u002FCT scan",{"label":15,"type":10,"description":16,"interventionNames":17},"Group B","22 patients with known cardiac sarcoidosis",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Group C","Up to 10 patients with clinically suspected or confirmed acute lymphocytic myocarditis",[13],{"label":23,"type":10,"description":24,"interventionNames":10},"Group D","22 patients with NET without known inflammatory heart disease who have previously been scanned with 64Cu-DOTATATE PET\u002FCT as part of their routine diagnostic work-up or follow-up (control group)",[26],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":10},"DIAGNOSTIC_TEST","64Cu-DOTATATE PET\u002FCT scan","Patients in group A-C will have a 64Cu-DOTATATE PET\u002FCT scan performed in addition to routine clinical procedures. Group D has had 64Cu-DOTATATE PET\u002FCT performed as part of their clinical diagnostic work-up or follow-up; these data are retrospectively identified and included in the study, and group D will not be subject to any scans in the study.",[9,15,19],[32],{"name":33,"affiliation":5,"role":34},"Finn Gustafsson, MD,PhD,DMSc","PRINCIPAL_INVESTIGATOR",[36,40],{"name":33,"role":37,"phone":38,"phoneExt":10,"email":39},"CONTACT","+45 35456340","finn.gustafsson@regionh.dk",{"name":41,"role":37,"phone":42,"phoneExt":10,"email":43},"Adelina Yafasova, MD","+45 35456252","adelina.henney.yafasova@regionh.dk",[45],{"facility":46,"status":47,"city":48,"state":10,"zip":10,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Rigshospitalet","RECRUITING","Copenhagen","Denmark","DK",{"type":52,"coordinates":53},"Point",[54,55],12.56553,55.67594,{"lat":55,"lon":54},[58,59],{"name":33,"role":37,"phone":38,"phoneExt":10,"email":39},{"name":41,"role":37,"phone":42,"phoneExt":10,"email":43},{"type":34,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Finn Gustafsson","Professor","100526159","macrophage-petct-imaging-using-64cu-dotatate-for-the-diagnosis-of-cardiac-sarcoidosis-100526159",false,"NCT06131112","Macrophage PET\u002FCT Imaging Using 64Cu-DOTATATE for the Diagnosis of Cardiac Sarcoidosis","Macrophage PET\u002FCT Imaging for the Diagnosis of Cardiac Sarcoidosis","CuDOSIS","Inclusion Criteria:\n\n* Age =\\> 18 years\n* Group A: 22 patients with clinically suspected cardiac sarcoidosis Group B: 22 patients with known cardiac sarcoidosis Group C: Up to 10 patients with clinically suspected or confirmed acute lymphocytic myocarditis Group D: 22 patients with NET without known inflammatory heart disease who have previously been scanned with 64Cu-DOTATATE PET\u002FCT as part of their routine diagnostic work-up or follow-up (control group)\n\nExclusion Criteria:\n\n* Severe obesity (weight \\> 140 kg)\n* Pregnancy (negative point-of-care urine\u002Fserum human chorion gonadotropin is required in all fertile women)\n* Severe claustrophobia\n* Known allergy to 64Cu-DOTATATE\n* Clinically critical condition which makes PET\u002FCT impossible\n* Diabetes with insulin dependence","ALL","18 Years",{"count":74,"type":75},76,"ESTIMATED","OBSERVATIONAL","The purpose of the CuDOSIS study is to examine the diagnostic value of activated macrophage imaging in patients with or under evaluation for cardiac sarcoidosis. The PET\u002FCT tracer 64Cu-DOTATATE is used as a tool to identify activated macrophages. The trial is an open-label prospective study. The study will include 54 participants from the Department of Cardiology and the Department of Clinical Physiology, Nuclear Medicine, and PET at Rigshospitalet. Further, the study will include data from 22 patients with NET who have been scanned with 64Cu-DOTATATE PET\u002FCT previously as negative controls.\n\nParticipants will be included in the following groups:\n\nGroup A: 22 patients with clinically suspected cardiac sarcoidosis Group B: 22 patients with known cardiac sarcoidosis Group C: Up to 10 patients with clinically suspected or confirmed acute lymphocytic myocarditis Group D: 22 patients with NET without known inflammatory heart disease who have previously been scanned with 64Cu-DOTATATE PET\u002FCT as part of their routine diagnostic work-up or follow-up (control group)",[79],"Cardiac Sarcoidosis","2023-11-14",{"date":82,"type":83},"2023-11-18","ACTUAL",{"date":85,"type":83},"2023-11-01",{"date":87,"type":75},"2027-01",{"name":5,"class":6},1]